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Abstract
Background: The clinical guidelines related to the primary prevention of Alzheimer’s disease (AD) have focused on
the management of vascular risk factors. However, the link between vascular risk factors and AD in older adults
remains unclear. This study aimed to determine the association between vascular risk factors and subsequent AD in
178,586 older adults (age ≥ 65 years).
Methods: Participants were recruited from 2009 through 2010 and followed up for 6 years. We assessed various
vascular risk factors (total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein
cholesterol [HDL-C], triglycerides [TG], fasting glucose [FG], systolic blood pressure [SBP], diastolic blood pressure
[DBP], pulse pressure [PP], and body mass index [BMI]) and their association with AD incidence, categorizing each
vascular factor using current clinical guidelines.
Results: AD was observed in 6.0% of participants at follow-up. All lipid profiles (TC, LDL-C, HDL-C and TG)
were positively associated with the risk of AD. SBP and PP were in negative associations with AD, and DBP
was positively associated with AD. BMI exhibited a negative association with AD incidence. We found no
significant association between FG and AD risk. The sex difference was observed to have effects on vascular
risk factors.
Conclusions: In this study, we comprehensively investigated the association between eight vascular risk
factors and the risk of incident AD. Our findings suggest that multiple vascular risk factors are related to the
development of AD in older adults. These results can help inform future guidelines for reducing AD risk.
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Background
Alzheimer’s disease (AD) is among the most prevalent
neurological disorders, accounting for 10.2% of the global
disability-adjusted life year (DALY) [1]. Moreover, re-
searchers have projected that over 60 million individuals
worldwide will be diagnosed with AD by the year 2050 [2].
Trials for AD-modifying drugs have yielded disappointing
results, increasing the need for primary prevention efforts.
Current guidelines related to the primary prevention
of AD focus on the modification of vascular risk factors
(e.g., dyslipidemia, blood pressure [BP], fasting glucose
[FG], or weight) [3–7]. Vascular risk factors in midlife
and late-life, associated with the risk of AD, showed
inconsistent profiles, with midlife vascular risk factors
increasing the AD risk, contrary to late-life factors [8].
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Midlife hypertension has been reported to increase AD
dementia risk [9], while late-life hypertension has an in-
consistent association with AD dementia risk in the same
research. The FG level in midlife was also reported to
have an increased association with AD risk which was in
line with late-life poor glucose control [10], but this asso-
ciation was not consistent with previous studies [11]. The
association between lipid profile in midlife and late-life
with AD risk is similar to that of BP. Increased lipid level
in midlife was reported to increase AD risk [12], but
other researchers reported mixed results with interven-
tions [13, 14]. However, late-life lipid level and AD risk
were more complicated, demonstrating either opposite re-
sults or no significance [15]. Midlife obesity is an estab-
lished risk factor for AD, whereas late-life obesity has
been proposed as a protective state, exhibiting reverse
causation [16]. As it could be supported by these com-
plex reports in midlife and late-life vascular risk factor
studies, the preventive effect of modifying vascular risk
factors in older adults is still insufficient.
Additionally, the majority of previous studies have
examined a limited number of risk factors at a time,
and some of these studies have not considered the
confounding effects of comorbid illnesses or related
modifiable lifestyle factors [17]. The difference on the
risk of AD linked to vascular risk factors based on
sex is also an emerging issue to be explored. This dif-
ference has been related to different factors between
male and female including systematic inflammation,
metabolic condition, vascular dysfunctions and
immobilization [18]. In this nationwide population-
based study of older adults, we aimed to investigate
the association between multiple vascular risk factors
and subsequent AD after comprehensive adjustment
for covariates. We hypothesized that the vascular risk
factors in older adults could have an association with
the risk of AD, concordant with recent guidelines
suggested in midlife vascular risk factors and AD.
Methods
Data source
Data for this nationwide population-based study of older
adults in South Korea were obtained from the National
Health Insurance Service-Senior Cohort (NHIS-SC)
database. The study was approved by the Institutional
Review Board of Seoul National University Bundang
Hospital, which waived the requirement for informed
consent due to the nature of the study. All data were
anonymized to maintain confidentiality.
The NHIS is the universal insurance provider for all
of South Korea, launched in 2000 as a single-payer
system combining more than 366 medical insurance
payers [19]. NHIS collects medical records for all citi-
zens, including data related to healthcare utilization
(outpatient visits or admission), prescription medica-
tions, national health examination results, and demo-
graphics, to construct the National Health Insurance
Database (NHID). Among the five national cohorts
established by the NHIS, the NHIS-SC includes data
from 558,147 older adults taken from the total eli-
gible population (age ≥ 60 years; 5.5 million people in
2002) using a simple random sampling method. The
NHIS-SC participants were followed up from January
1, 2002, until December 31, 2015.
Study design and population
We did a nationwide retrospective cohort study using
the NHIS-SC data. The assessments of several vascu-
lar risk factors (total cholesterol [TC], low-density
lipoprotein cholesterol [LDL-C], high-density lipopro-
tein cholesterol [HDL-C], and triglycerides [TG]) were
initiated in 2009. Therefore, we selected a total of
206,046 participants who had undergone a national
health examination at least once between 2009 and
2010 from the 558,147 NHIS-SC participants. Then,
participants who had died before 2010 (n = 710), diag-
nosed with any type of dementia (n = 16,969), with in-
complete information regarding risk factors and
covariates, and outlier values (exceeding the mean ± 4
standard deviations) for any risk factors or covariates
(n = 9781) were excluded. The final study population
included 178,586 participants (Fig. 1).
Construction of key variables
Vascular risk factors collected included TC (mg/dL), LDL-
C (mg/dL), HDL-C (mg/dL), TG (mg/dL), FG (mg/dL),
systolic BP (SBP, mmHg), diastolic BP (DBP, mmHg), and
body mass index (BMI, units). We assessed levels of these
variables measured during the national health examination
in 2009 or 2010. When health examinations were per-
formed in both 2009 and 2010, the levels from 2010 were
used. For the main analyses, continuous variables were cat-
egorized according to the current Korean guidelines for
vascular risk factors [20] and the categorized variables
were analyzed as the main variables. The reference levels
were < 200mg/dL for TC, < 100mg/dL for LDL-C, ≥ 60
mg/dL for HDL-C, < 150mg/dL for TG, < 70mg/dL for
FG, < 120mmHg for SBP, < 80mmHg for DBP, and < 18.5
for BMI. Cutoff values for each category of the vascular
risk factors are presented in Additional file 1: Table S1.
We also constructed the pulse pressure (PP) variable by
subtracting DBP from SBP. PP is considered a surrogate
marker for arterial stiffness [21] and known to be an inde-
pendent predictor for cardiovascular diseases. The PP vari-
able was categorized by its quartile cutoff due to the
absence of the referent level for PP, and the first quartile
(Q1) was used as a referent level. The quartile cutoffs were
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42mmHg for Q1–Q2, 50mmHg for Q2–Q3, and 60
mmHg for Q3–Q4.
Incident AD was regarded as the primary outcome.
For this study, AD incidence was defined as the first
healthcare utilization according to the International
Classification of Diseases, Tenth Revision (ICD-10)
codes F00 or G30 (primary or secondary diagnosis), ac-
companied by a documented history of using cognition-
enhancing medications (donepezil, rivastigmine, galanta-
mine, or memantine) [22].
Statistical analysis
We conducted a survival analysis using the Cox propor-
tional hazards regression model, to estimate hazard ratios
(HRs) for vascular risk factors associated with subsequent
AD incidence. Survival time was calculated from January
1, 2010, to the date of AD incidence, death, or the end of
follow-up (December 31, 2015), whichever occurred first.
Each vascular risk factor (categorical, see Additional file 1:
Table S1) was first evaluated in the age- and sex-adjusted
Cox model. Age was included as a continuous variable.
The subsequent fully adjusted Cox model included house-
hold income (categorical, medical aid, low [1st–3rd decile],
middle [4th–7th decile], or high [8th–10th decile]), smok-
ing status (categorical, never, ex-smoker, or current
smoker), alcohol consumption (categorical, rarely [0–2
days/week], light [3–4 days/week], or heavy [5–7 days/
week]), exercise (categorical, yes or no [1–7 days/week]),
hemoglobin (continuous, g/dL), frequency of healthcare
utilization (categorical, first, second, third, or fourth quar-
tiles), depression (categorical, yes or no), Charlson Comor-
bidity Index (continuous), medication history (categorical
[yes or no] for each medication category [dyslipidemia
medication, antidiabetic medication, antihypertensive
medication, antidepressants, benzodiazepines or sleeping
aids, and antiplatelet medication]), and all other vascular
risk factors (continuous). Household income was esti-
mated based on insurance premiums using NHIS data.
The frequency of healthcare utilization, comorbidities, and
medication history was calculated based on the data from
2002 to 2010. In the analysis of TC as a major risk factor,
LDL-C was excluded in the full model, and in the analysis
for PP, DBP was excluded. In analyses for all other vascu-
lar risk factors, TC was excluded due to the high correl-
ation between TC and LDL-C. Multicollinearity between
all covariates was tested using a variance inflation factor
(VIF), which revealed no significant collinearity (VIF < 2
for all variables). P values for linear trends were also calcu-
lated by treating median values of each categorical group
as continuous variables (e.g., 173mg/dL, 217mg/dL, and
257mg/dL for each group of TC). The proportional haz-
ard (PH) assumption was satisfied both graphically and
statistically using Schoenfeld residuals. No variables vio-
lated the PH assumption.
We examined prescription records for dyslipidemia medi-
cation, antidiabetic medication, and antihypertensive medi-
cation during the first 3 years of follow-up for all
participants, who were then stratified into two groups ac-
cording to each prescription history. Stratified analyses were
performed to investigate whether medication intake during
the follow-up period modified the association between vas-
cular risk factors and AD incidence. Analyses were also
stratified by sex to assess the potential effect of sex. Signifi-
cant differences between the two groups were examined
using an interaction term between vascular risk factor vari-
ables and group indicator variables in the total dataset.
Two-sided analyses were conducted at a significance
level of .05, and 95% CIs are reported. SAS Enterprise
Guide version 7.2 (SAS Institute Inc) and R Studio ver-
sion 1.0.136 (RStudio Inc: packages survival version
2.43-3 and survminer version 0.4.3) were used to
perform the analyses.
Fig. 1 Flow diagram of the study population
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Results
Characteristics of the study population
During the 6-year follow-up period, 10,732 (6.0%) partic-
ipants had incident AD. Among them, 94.8% of the pa-
tients were prescribed with donepezil, rivastigmine, and
galantamine for mild or moderate severity, while the rest
of patients (5.2%) were prescribed high doses of donepe-
zil and memantine, which are approved for moderate or
severe dementia. Table 1 presents the descriptive charac-
teristics of the study participants in the incident AD and
non-AD groups. Female sex, older age, medical assist-
ance, smoking, alcohol consumption, frequent exercise,
frequent healthcare utilization, comorbidities (including
depression), and a history of medication use were more
common in the AD group. Besides, the AD group exhib-
ited higher TC, LDL-C, TG, and FG levels than the non-
AD group. Hemoglobin levels and BMI were lower in
the AD group than in the non-AD group.
Vascular risk factors and the risk of subsequent AD
The cumulative incidence of AD events according to the
categorized vascular risk factors based on the current
Korean guidelines is presented in Fig. 2. Compared to
the referent levels, higher levels of TC, LDL-C, and TG
were associated with a higher cumulative incidence of
AD, whereas higher levels of BMI showed a lower cumu-
lative AD incidence. Clear linear trends were not ob-
served in other vascular risk factors.
In the age- and sex-adjusted models, highest levels of
TC (≥ 240mg/dL) and TG (200–499mg/dL) showed a
significantly higher risk of AD (TC: HR = 1.085 [95% CI =
1.025–1.149], TG: HR = 1.101 [95% CI = 1.044–1.161])
compared to the referent levels (TC, < 200mg/dL; TG, <
150mg/dL), whereas highest SBP levels (≥ 140mmHg vs.
< 120mmHg) showed a significantly lower AD risk (HR =
0.887 [95% CI = 0.840–0.946]). Other vascular risk factors
exhibited no significant associations with the risk of AD
(Table 2 and Additional file 1: Table S2).
The fully aHRs for AD incidence by vascular risk factors
categorized according to the current Korean guidelines are
presented in Fig. 3, Table 2, and Additional file 1: Table S2.
The associations of highest levels of TC, TG, and SBP
with the incident AD remained significant in the full
model (TC: HR = 1.089 [95% CI = 1.025–1.156], TG: HR =
1.094 [95% CI = 1.034–1.156], SBP: HR = 0.827 [95% CI =
0.771–0.888]). The risk of incident AD increased accord-
ing to LDL-C levels until they reached 190mg/dL (HR =
1.116 [95% CI = 1.039–1.199] vs. < 100mg/dL), at which
point the risk decreased (HR = 1.085 [95% CI = 0.966–
1.218]). In contrast, the risk of incident AD increased ac-
cording to LDL-C levels until they reached 190mg/dL
(HR = 1.116 [95% CI = 1.039–1.199] vs. < 100mg/dL), at
which point the risk decreased (HR = 1.085 [95% CI =
0.966–1.218]). In contrast, HDL-C levels of 40–59mg/dL
were associated with a significantly lower risk of AD
events (HR = 0.945 [95% CI = 0.904–0.988]) than the refer-
ence level (≥ 60mg/dL), while levels < 40mg/dL did not
significantly reduce the risk (HR = 0.941 [95% CI = 0.882–
1.004]). The highest DBP levels (≥ 90mmHg) were associ-
ated with an increased risk of incident AD (HR = 1.110
[95% CI = 1.037–1.188]) compared to the referent level (<
80mmHg). Finally, AD risk decreased according to BMI
until reaching 35.0 kg/m2 (HR = 0.901 [95% CI = 0.780–
1.040]), following which non-significant increases in risk
were observed (HR = 1.292 [95% CI = 0.710–2.349]). All
vascular risk factors except FG and BMI showed a signifi-
cant linear trend (P for trend = 0.019 to < 0.0001). The
substantial differences in the results of the age- and sex-
adjusted model and the fully adjusted model could be at-
tributed to the comprehensive adjustment of various con-
founders (Additional file 1: Table S3).
Figure 4 shows the cumulative incidence of AD events
according to the quartile group (Q1–Q4) of PP. Q2–Q4
levels of PP were associated with a lower risk of AD than
the Q1 level. In the age- and sex-adjusted model, the Q4
level of PP was significantly associated with a lower risk of
AD events (HR for Q4 vs. Q1 = 0.858 [95% CI = 0.815–
0.903]). This association remained significant in the fully
adjusted model (HR for Q4 vs. Q1 = 0.840 [95% CI =
0.780–0.905]) and exhibited a decreasing linear trend (P
for trend < 0.0001) (Fig. 4 and Additional file 1: Table S4).
Subgroup analyses according to sex and medication history
The sex-specific associations between incident AD and
vascular risk factors are shown in Table 2 and Add-
itional file 1: Table S5, Table S6. The positive association
between AD and the highest TC levels (≥ 240 mg/dL vs.
< 200 mg/dL) was significant in women (HR = 1.102
[95% CI = 1.028–1.181]), but not significant in men
(HR = 1.055 [95% CI = 0.929–1.198]). In women, higher
levels of LDL-C than the referent level (< 100 mg/dL)
were associated with a significantly increased risk of AD
until they reached 190 mg/dL (HR = 1.150 [95% CI =
1.056–1.252]), at which point the risk decreased (HR =
1.095 [95% CI = 0.961–1.247]), and lower levels of HDL-
C than the referent level (≥ 60mg/dL) were associated
with a significantly lower risk of AD (40–59mg/dL:
HR = 0.943 [95% CI = 0.894–0.995], < 40 mg/dL: HR =
0.913 [95% CI = 0.840–0.991], trend P = 0.01). In con-
trast, these associations with LDL-C and HDL-C were
not significant in men. The positive association of AD
with higher TG levels than the referent level (< 150mg/
dL) was observed in both sex groups. In men, TG levels
of 150–199 mg/dL (HR = 1.100 [95% CI = 1.103–1.205])
were significant, but levels ≥ 200 mg/dL (HR = 1.084
[95% CI = 0.978–1.201]) were not significant. In women,
only levels ≥ 200mg/dL exhibited a significant associ-
ation (HR = 1.100 [95% CI = 1.030–1.176]). Higher DBP
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Table 1 Descriptive characteristics of the study population
No. (%) of participants, vascular risk factors
Total (n = 178,586) AD (n = 10,732) Non-AD (n = 167,854) P value
Sex* < 0.0001
Male 81,242 (45.5) 3742 (34.9) 77,500 (46.2)
Female 97,344 (54.5) 6990 (65.1) 90,354 (53.8)
Age group* < 0.0001
65 to 69 years 23,471 (13.1) 74 (0.7) 23,397 (13.9)
70 to 74 years 80,333 (45.0) 2352 (21.9) 77,981 (46.5)
75 to 79 years 48,208 (27.0) 3898 (36.3) 44,310 (26.4)
Older than 80 years 26,574 (14.9) 4408 (41.1) 22,166 (13.2)
Income, deciles* < 0.0001
Medical aid 1899 (1.1) 258 (2.4) 1641 (1.0)
Low (1st–3rd decile) 36,433 (20.4) 2037 (19.0) 34,396 (20.5)
Middle (4th–7th decile) 48,421 (27.1) 2832 (26.4) 45,589 (27.2)
High (8th–10th decile) 91,833 (51.4) 5605 (52.2) 86,228 (51.4)
Lifestyles
Smoking status* < 0.0001
Never smoking 130,940 (73.3) 8475 (79.0) 122,465 (73.0)
Ex-smoking 26,613 (14.9) 1230 (11.5) 25,383 (15.1)
Current smoking 21,033 (11.8) 1027 (9.6) 20,006 (11.9)
Alcohol consumption* < 0.0001
Rarely (0–2 days/week) 158,170 (88.6) 9795 (91.3) 148,375 (88.4)
Light (3–4 days/week) 9275 (5.2) 376 (3.5) 8899 (5.3)
Heavy (5–7 days/week) 11,141 (6.2) 561 (5.2) 10,580 (6.3)
Exercise* < 0.0001
No exercise 121,405 (68.0) 7795 (72.6) 113,610 (67.7)
Exercise 57,181 (32.0) 2937 (27.4) 54,244 (32.3)
Comorbidities
Depression* 14,075 (7.9) 1270 (11.8) 12,805 (7.6) < 0.0001
Charlson Comorbidity Index* < 0.0001
0 21,574 (12.1) 975 (9.1) 20,599 (12.3)
1 40,912 (22.9) 2014 (18.8) 38,898 (23.2)
≥ 2 116,100 (65.0) 7743 (72.2) 108,357 (64.6)
Healthcare visit frequency*,† < 0.0001
First quartile 44,748 (25.1) 1904 (17.7) 42,844 (25.5)
Second quartile 44,669 (25.0) 2325 (21.7) 42,344 (25.2)
Third quartile 44,595 (25.0) 2751 (25.6) 41,844 (24.9)
Fourth quartile 44,574 (25.0) 3752 (35.0) 40,822 (24.3)
Medication history*
HMG-CoA reductase inhibitors 41,904 (23.5) 2611 (24.3) 39,293 (23.4) 0.029
Antidiabetic medication 28,439 (15.9) 2056 (19.2) 26,383 (15.7) < 0.0001
Antihypertensive medication 106,098 (59.4) 6101 (62.4) 99,397 (59.2) < 0.0001
Antidepressants 10,318 (5.8) 1028 (9.6) 9290 (5.5) < 0.0001
Benzodiazepine and sleep pill 47,203 (26.4) 3835 (35.7) 43,368 (25.8) < 0.0001
Antiplatelet medication 50,994 (28.6) 3491 (32.5) 47,503 (28.3) < 0.0001
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(≥ 90mmHg) was associated with an increased risk of in-
cident AD (HR = 1.158 [95% CI = 1.066–1.259]). How-
ever, increasing SBP (up to ≥ 140 mmHg) was linearly
associated with decreases in the risk of incident AD
(HR = 0.800, [95% CI = 0.734–0.873]) in women, but not
significant in men. Higher BMI levels than the referent
level (18.5 kg/m2) showed a significant negative associ-
ation with AD risk until reaching 35.0 kg/m2 (HR =
0.828 [95% CI = 0.702–0.978]) in women, whereas it
showed a positive non-significant association in men (≥
35.0 kg/m2: HR = 2.428 [95% CI = 0.062–9.792]). Com-
pared to Q1 levels, Q4 levels of PP were associated with
a lower risk of AD in both sex groups, but it was not sig-
nificant in men (Fig. 4 and Additional file 1: Table S4).
However, these differences were not significant for all
vascular risk factors (P for interaction = 0.09–0.77).
Furthermore, there was no evidence of an interaction
between vascular risk factors and medication during the
first 3 years of follow-up regarding incident AD (all P for
interaction > 0.10, Additional file 1: Table S7).
Discussion
In this nationwide population-based study of 178,586
Korean older adults, we investigated the association be-
tween eight vascular risk factors and the risk of incident
AD. As summarized in Fig. 3, lipid profiles including
TC, LDL-C, HDL-C, and TG exhibited positive associa-
tions with AD risk. SBP and BMI exhibited a negative
association with AD incidence, except for the highest
group. The risk of AD exhibited a significantly positive
association with DBP. Subgroup analyses revealed a sig-
nificant positive association between TC, LDL-C, HDL-
C, TG, DBP, and AD risk in women. Otherwise, a
significantly negative association between AD risk and
SBP was observed in women. A significant positive asso-
ciation between AD risk and TG was observed in men.
The largest recent meta-analysis, which included 23,338
participants, reported no association between levels of lipid
profiles (including TC, LDL-C, and TG) in late-life and AD
risk [23]. However, this analysis did not include other po-
tentially confounding vascular risk factors such as BP, FG,
or BMI. We observed a positive association between AD
risk and lipid profiles including TC, LDL-C, and TG, con-
sistent with recent guidelines [24]. The association between
increased cholesterol levels and risk of AD is yet to be fully
understood, for the levels in the brain are independent of
peripheral tissues due to the blood-brain barrier. However,
considering high-fat diets are related to amyloid-beta (Aβ)
accumulation, the increased flux of oxysterols to the brain
caused by this diet could provide an explanation for our
results [25]. Increased influx of oxysterols to the brain is
reported to accelerate cognitive deficits in AD [25].
Notably, the direction of the association between HDL-
C and AD risk differed from that reported in previous ob-
servational studies [26, 27] and guidelines. A recent meta-
analysis reported no significant association between HDL-
C and AD risk [23]. The protective effects of HDL-C on
AD risk have been observed in middle-aged adults, while
studies examining patients ≥ 70 years of age have reported
no such association [28]. Furthermore, these observational
studies had limited sample sizes of < 10,000 [23]. Accumu-
lating evidence suggests that steady-state HDL-C levels
are not causally protective against cardiovascular disease
[29, 30]. Previous studies have shown that aging alters
HDL-C composition, resulting in functional impairment,
especially in antioxidant properties [31]. Not HDL
Table 1 Descriptive characteristics of the study population (Continued)
No. (%) of participants, vascular risk factors
Total (n = 178,586) AD (n = 10,732) Non-AD (n = 167,854) P value
Laboratory findings, mean (SD)
Cholesterol level, mg/dL‡
Total cholesterol 196.4 (38.4) 198.6 (39.3) 196.3 (38.4) < 0.0001
LDL-C 116.2 (35.3) 117.6 (35.8) 116.1 (35.2) < 0.0001
HDL-C 52.8 (13.4) 52.9 (13.7) 52.8 (13.4) 0.211
Triglyceride 135.6 (68.6) 138.6 (69.9) 135.4 (68.5) < 0.0001
Fasting glucose, mg/dL‡ 101.9 (21.0) 102.8 (22.3) 101.9 (20.9) < 0.0001
Hemoglobin, g/dL‡ 13.3 (1.5) 13.0 (1.4) 13.3 (1.5) < 0.0001
Physical examination findings, mean (SD)‡
Systolic blood pressure, mmHg 130.3 (15.9) 130.4 (16.4) 130.3 (15.9) 0.534
Diastolic blood pressure, mmHg 78.0 (9.8) 78.1 (10.1) 78.1 (9.8) 0.728
Body mass index, kg/m2 23.8 (3.1) 23.5 (3.2) 23.8 (3.1) < 0.0001
*Group comparisons by chi-squared tests
†The fourth quartile group had the highest frequency of medical visits
‡Group comparisons by T tests
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quantity but HDL functional quality is thought to impact
vascular risks by altered oxidation, inflammation, and
thrombosis especially with reverse cholesterol transport
[30, 31]. These age-related changes in HDL-C could be re-
lated to the different effects of HDL-C on AD according
to age group. Due to the age restrictions of the sample, we
Fig. 2 The Kaplan-Meier estimates of incidence of Alzheimer’s disease by vascular risk factors categorized based on the current Korean guidelines
among older adults
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could not include a middle age comparison population. In
addition, our data did not include variables for HDL qual-
ity. Further studies including HDL-C composition and
function across diverse age groups are warranted.
We observed a conflicting effect of DBP and SBP on AD.
We found a negative association between SBP and AD, and
a positive association between DBP and AD. These results
were also confirmed in analysis for the association between
PP and AD (Fig. 4). The association between BP in older
adults and cognitive impairment remains uncertain, and
the results of observational studies involving older adults
are inconsistent [32–34]. Several randomized controlled tri-
als have suggested that lowering BP exerts beneficial effects
on cognitive function; however, the evidence is still limited
[35–37]. Although the World Health Organization recom-
mends antihypertensive treatment for dementia prevention
[24], the American College of Physicians and the American
Academy of Family Physicians [38] had previously sug-
gested less strict SBP control for maintaining cognitive
health in older adults. Our findings may indicate that this
discrepancy is due to the different effects of SBP and DBP
on dementia. Inverse associations of SBP with the risk of
AD have been reported in large, population-based health
studies [39] and recently supported by a Mendelian
randomization study of AD [40]. Although SBP cannot
fully represent sufficiency of cerebral blood flow, SBP is
negatively associated with AD incidence, which could sug-
gest sufficient cerebral oxygen levels follow insufficient
Fig. 3 Risk of Alzheimer’s disease in older adults according to vascular risk factors categorized based on the current Korean guidelines. Vascular
risk factors were sorted in order of guideline. The subjects with the recommended value (not the lowest value) were used as a reference group
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cerebral blood flow. Whether this association is derived
from cerebral blood flow related to SBP or from the usage
of antihypertensive medication needs further neuroimaging
research in relation to cerebral blood flow. A previous re-
port on midlife DBP could support our finding, suggesting
DBP as the strongest predictor of progression of arterial
stiffness, leading to AD [41]. We found a negative asso-
ciation between PP and AD risk, which was inconsist-
ent with previous reports that showed that higher PP in
midlife increases AD risk and Aβ transport dysfunction
[42]. This discrepancy suggests that the effect of PP on
AD risk could differ according to the age group. How-
ever, given the observational nature of our study, we
could not determine whether there is a causal associ-
ation between BP and dementia risk.
The association between BMI and AD risk in the
present study is consistent with that reported in previous
studies [16]. The protective effect of BMI may be related
to the role of leptin in regulating hippocampal synaptic
plasticity [43] and the additional positive effects of muscle
preservation. However, these findings should be inter-
preted with caution to avoid a potential reverse causation
effect (i.e., weight loss in preclinical AD).
Our results regarding the association between FG and
AD risk are inconsistent with those of recent clinical tri-
als that tested the effects of controlling serum glucose
levels on reducing the risk of AD [44, 45]. However,
these trials were conducted in patients with diabetes
mellitus or measured restricted outcomes such as an
amyloid deposition [44]. The association between FG
and AD could differ in the general population.
In the present study, we observed differences in the as-
sociation between lipid profiles and AD risk according
to sex. TC and LDL-C were independent risk factors for
AD in the female subgroup, whereas TG was a risk fac-
tor in both males and females. The incidence, risk fac-
tors, clinical symptoms, and progression of AD may
differ between men and women [46–48]. Such sex-based
differences may be due to the differences in lipid metab-
olism and hormone levels. For example, estrogen, which
affects cholesterol removal from the liver, plays a signifi-
cant role in sex-specific morbidity related to vascular
risk factors [49]. These distinctive differences may also
be driven by different apolipoprotein profiles in men and
women. Further studies are required to determine the
mechanisms underlying such sex-based differences.
The effect size for associations between vascular risk
factors and AD risk was small in the present study
(Fig. 3). Moreover, medication use did not modify this
association (Additional file 1: Table S7). These findings
suggest that management of vascular risk factors alone
would not be enough to reduce AD risk. An integrative
Fig. 4 The Kaplan-Meier estimates of incidence of Alzheimer’s disease by pulse pressure categorized based on quartiles among older adults
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approach including management of vascular risk factors,
lifestyle modifications and cognitive training could have
drawn contribution to AD prevention in older adults
[50]. However, it should be noted that the effect of con-
trolling vascular risk factors may be stronger in early AD
stages or mild cognitive disorders. Once the pathological
change has progressed enough to require medication,
prevention efforts could not reach significant effects.
This could explain the small effect size of vascular risk
factors on AD and the little significance of medication
modification in our results.
Our large-scale study is advantageous in that we utilized
nationwide real-world data representing older adults in
the Korean population. Moreover, we addressed multiple
vascular risk factors and stratified analyses according to
sex and age groups. As most other studies have focused
on midlife vascular risk factors related to the risk of de-
mentia, our findings may provide further explanations,
representing a clear association with those related to the
risk in older adults. This study also had several limitations.
First, although we comprehensively adjusted for various
confounders including socioeconomic or lifestyle factors,
we did not consider potential confounders such as educa-
tion, occupational attainment, exercise, diet, sufficient
sleep, family history, and genetics (apolipoprotein E geno-
type). The lack of information on the level of hemoglobin
A1c, a standard tool to determine average blood glucose
control levels, could be a significant limitation, which
needs to be elaborated through future research represent-
ing actual glucose control. Second, the operational
definition of AD may be associated with misdiagnosis or
underdiagnosis. However, the rate of AD in our study
population was similar to rates reported in epidemio-
logical studies conducted in South Korea [51]. Addition-
ally, we included prescription information in the
operational criteria to improve the accuracy of diagnosis.
In South Korea, clinicians are required to document clin-
ical diagnoses of dementia as well as the results of neuro-
psychological tests in order to prescribe the medications
outlined in our inclusion criteria. Dementia ascertainment,
defined as prescribing cognitive enhancer, could have lim-
ited information to fully represent the actual onset of AD,
considering the insidious progress of AD in the clinical
situation. Lack of information regarding biomarkers and
AD confirmation via imaging might have led to the limita-
tion of a heterogeneous group with numerous contribut-
ing pathological substrates. The lack of information
related to the severity stage of AD also had limitation to
observe association between the role of vascular risk
factors and the course of AD. Third, because the study
population included individuals from a single country, our
findings may not be generalizable to people from other
countries. Fourth, given the observational nature of our
study, we could not determine causal relationships
between vascular risk factors and AD risk. And careful in-
terpretation should be conducted with respect to reverse
causation effect, for changes in vascular metrics occur
proximal to the onset of major neurocognitive dysfunction
rather than early stages of AD pathophysiology. Last, since
our study population was based on the National Health
Insurance Service-Senior Cohort (≥ 60 years), we could
not investigate whether midlife and later life vascular risk
factors have different effects on incident AD. Future stud-
ies examining the differences among midlife and later life
vascular risk factors from a same population would be
informative.
Conclusions
In the present study, we observed a positive association
between AD risk and TC, LDL-C, HDL-C, TG, and DBP
among older adults. Further, SBP, BMI, and PP exhibited
robust negative associations with AD risk. Associations
between AD and TC, LDL-C, HDL-C, and DBP differed
according to sex. More elaborate, prospective studies are
required to gain a greater understanding of the association
between vascular risk factors and AD in older adults.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13195-020-00690-7.
Additional file 1: Table S1. The current Korean guidelines for vascular
risk factors. Table S2. Detailed results for risk of Alzheimer’s disease
according to vascular risk factors. Table S3. Adjusted hazard ratios of risk
factors associated with incident Alzheimer’s disease by Cox proportional
hazards model (n= 178,586). Table S4. Risk of Alzheimer’s disease in
older adults according to pulse pressure categorized based on quartiles.
Table S5. Risk of Alzheimer’s disease according to vascular risk factors in
male subgroup (n=81,242). Table S6. Risk of Alzheimer’s disease
according to vascular risk factors in female subgroup (n=97,344). Table
S7. Stratified analysis according to medications prescription during the
first 3 years of follow-up.
Abbreviations
AD: Alzheimer’s disease; aHR: Adjusted hazard ratio; Aβ: Amyloid-beta;
BP: Blood pressure; BMI: Body mass index; DALY: Disability-adjusted life year;
DBP: Diastolic blood pressure; FG: Fasting glucose; HDL-C: High-density
lipoprotein cholesterol; ICD-10: International Classification of Diseases, Tenth
Revision; LDL-C: Low-density lipoprotein cholesterol; NHID: National Health
Insurance Database; NHIS-SC: National Health Insurance Service-Senior Co-
hort; PH: Proportional hazard; PP: Pulse pressure; SBP: Systolic blood pressure;




HL conceived and designed the study, acquired and analyzed the data,
interpreted the study findings, and drafted the manuscript. KK conceived
and designed the study; defined the exclusion criteria and exposure,
outcome, and covariate categories; interpreted the study findings; and
drafted the manuscript. YCL, SK, HHW, TYY, EML, JMK, ML, and DKK designed
the study; defined the exclusion criteria and exposure, outcome, and
covariate categories; interpreted the study findings; and drafted the
manuscript. WM conceived and designed the study, interpreted the study
findings, supervised and directed the conduct of the study, and critically
Lee et al. Alzheimer's Research & Therapy          (2020) 12:117 Page 12 of 14
reviewed the manuscript. The corresponding author attests that all listed
authors meet authorship criteria and that no others meeting the criteria
have been omitted. WM is the guarantor of the work. HL and KK contributed
equally to this work as co-first authors. All authors read and approved the
final manuscript.
Funding
This work was supported by the National Research Foundation of Korea
(NRF) Grant funded by the Ministry of Science and ICT (Information and
Communication Technologies), South Korea [grant number NRF-
2018R1C1B6001708; W Myung], and by the Soonchunhyang University Re-
search Fund [H Lee]. The funding source was not involved in the design and
conduct of the study; collection, management, analysis, and interpretation of
the data; preparation, review, or approval of the manuscript; and decision to
submit the manuscript for publication.
Availability of data and materials
This study is based on National Health Insurance Service (NHIS) registry data
in South Korea (NHIS-2018-2-198). Because these data belong to the NHIS,
the authors are not permitted to share them, except in aggregate (as, for
example, in a publication). However, interested parties can obtain the data
on which the study was based by submitting a research protocol to the
NHIS (https://nhiss.nhis.or.kr/bd/ab/bdaba000eng.do). The analytic/statistical
codes are available from the corresponding author (wjmyung@snubh.org,
WM), upon reasonable request.
Ethics approval and consent to participate
The study was approved by the Institutional Review Board of Seoul National
University Bundang Hospital, which waived the requirement for informed





The authors declare that they have no competing interests.
Author details
1Department of Health Administration and Management, College of Medical
Sciences, Soonchunhyang University, Asan, South Korea. 2Department of
Psychiatry, Veteran Health Service Medical Center, Seoul, South Korea.
3Samsung Advanced Institute for Health Sciences and Technology (SAIHST),
Sungkyunkwan University, Samsung Medical Center, Seoul, South Korea.
4Division of Endocrinology and Metabolism, Department of Medicine,
Wonkwang Medical Center, Wonkwang University School of Medicine, Iksan,
South Korea. 5Department of Health Science, Dongduk Women’s University,
Seoul, South Korea. 6Department of Psychiatry, Gil Medical Center, Gachon
University College of Medicine, Incheon, South Korea. 7The Department of
General Practice, Melbourne Medical School, The University of Melbourne,
Melbourne, Australia. 8Department of Psychiatry, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, South Korea.
9Department of Neuropsychiatry, Seoul National University Bundang Hospital,
Seongnam-si, South Korea.
Received: 12 April 2020 Accepted: 15 September 2020
References
1. Group GBDNDC. Global, regional, and national burden of neurological
disorders during 1990-2015: a systematic analysis for the Global Burden of
Disease Study 2015. Lancet Neurol. 2017;16(11):877–97.
2. Alzheimer's A. 2015 Alzheimer’s disease facts and figures. Alzheimers
Dement. 2015;11(3):332–84.
3. Kivipelto M, Mangialasche F. Alzheimer disease: to what extent can
Alzheimer disease be prevented? Nat Rev Neurol. 2014;10(10):552–3.
4. Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, Zhao QF, Li JQ, Wang J, Yu
JT. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol
Neurosurg Psychiatry. 2015;86(12):1299–306.
5. Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, Sperling
RA, Aisen PS, Roses AD, Welsh-Bohmer KA, et al. CAP--advancing the evaluation
of preclinical Alzheimer disease treatments. Nat Rev Neurol. 2016;12(1):56–61.
6. Sinclair AJ, Hillson R, Bayer AJ, National Expert Working G. Diabetes and dementia
in older people: a best clinical practice statement by a multidisciplinary National
Expert Working Group. Diabet Med. 2014;31(9):1024–31.
7. Gandy S, DeKosky ST. Toward the treatment and prevention of Alzheimer’s
disease: rational strategies and recent progress. Annu Rev Med. 2013;64:367–83.
8. Gottesman RF, Schneider AL, Zhou Y, Coresh J, Green E, Gupta N, Knopman
DS, Mintz A, Rahmim A, Sharrett AR, et al. Association between midlife
vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;
317(14):1443–50.
9. McGrath ER, Beiser AS, DeCarli C, Plourde KL, Vasan RS, Greenberg SM,
Seshadri S. Blood pressure from mid- to late life and risk of incident
dementia. Neurology. 2017;89(24):2447–54.
10. Wang KC, Woung LC, Tsai MT, Liu CC, Su YH, Li CY. Risk of Alzheimer’s
disease in relation to diabetes: a population-based cohort study.
Neuroepidemiology. 2012;38(4):237–44.
11. Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA,
Seshadri S. Diabetes mellitus and risk of developing Alzheimer disease:
results from the Framingham Study. Arch Neurol. 2006;63(11):1551–5.
12. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J,
Soininen H, Kivipelto M. Serum cholesterol changes after midlife and late-life
cognition: twenty-one-year follow-up study. Neurology. 2007;68(10):751–6.
13. Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, Bennett
DA. Statins, incident Alzheimer disease, change in cognitive function, and
neuropathology. Neurology. 2008;70(19 Pt 2):1795–802.
14. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are
associated with a reduced risk of Alzheimer disease regardless of lipophilicity.
The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80(1):13–7.
15. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M,
Manjon M, Girones X, Henry TL, Matsubara E, Zambon D, et al. Mild
hypercholesterolemia is an early risk factor for the development of
Alzheimer amyloid pathology. Neurology. 2003;61(2):199–205.
16. Pegueroles J, Jimenez A, Vilaplana E, Montal V, Carmona-Iragui M, Pane A,
Alcolea D, Videla L, Casajoana A, Clarimon J, et al. Obesity and Alzheimer’s
disease, does the obesity paradox really exist? A magnetic resonance
imaging study. Oncotarget. 2018;9(78):34691–8.
17. Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, Burke JR, Connolly
ES Jr, Dunbar-Jacob JM, Granieri EC, McGarry K, et al. Risk factors and
preventive interventions for Alzheimer disease: state of the science. Arch
Neurol. 2011;68(9):1185–90.
18. Volgman AS, Bairey Merz CN, Aggarwal NT, Bittner V, Bunch TJ, Gorelick PB,
Maki P, Patel HN, Poppas A, Ruskin J, et al. Sex differences in cardiovascular
disease and cognitive impairment: another health disparity for women? J
Am Heart Assoc. 2019;8(19):e013154.
19. Lee J, Lee JS, Park S-H, Shin SA, Kim K: Cohort Profile: The National Health
Insurance Service–National Sample Cohort (NHIS-NSC), South Korea. Int J
Epidemiol 2016:dyv319.
20. Committee for the Korean Guidelines for the Management of D. 2015
Korean guidelines for the management of dyslipidemia: executive summary
(English translation). Korean Circ J. 2016;46(3):275–306.
21. Asmar R, Darne B, el Assaad M, Topouchian J. Assessment of outcomes
other than systolic and diastolic blood pressure: pulse pressure, arterial
stiffness and heart rate. Blood Press Monit. 2001;6(6):329–33.
22. Kim CT, Myung W, Lewis M, Lee H, Kim SE, Lee K, Lee C, Choi J, Kim H, Carroll
BJ: Exposure to general anesthesia and risk of dementia: a nationwide
population-based cohort study. J Alzheimer's Dis 2018(Preprint):1–11.
23. Anstey KJ, Ashby-Mitchell K, Peters R. Updating the evidence on the
association between serum cholesterol and risk of late-life dementia: review
and meta-analysis. J Alzheimers Dis. 2017;56(1):215–28.
24. WHO. In: Risk reduction of cognitive decline and dementia: WHO
guidelines. edn. Geneva; 2019.
25. Mateos L, Akterin S, Gil-Bea FJ, Spulber S, Rahman A, Bjorkhem I, Schultzberg
M, Flores-Morales A, Cedazo-Minguez A. Activity-regulated cytoskeleton-
associated protein in rodent brain is down-regulated by high fat diet in vivo
and by 27-hydroxycholesterol in vitro. Brain Pathol. 2009;19(1):69–80.
26. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to
Alzheimer disease and vascular dementia. Arch Neurol. 2004;61(5):705–14.
27. Tynkkynen J, Hernesniemi JA, Laatikainen T, Havulinna AS, Sundvall J,
Leiviska J, Salo P, Salomaa V. Apolipoproteins and HDL cholesterol do not
Lee et al. Alzheimer's Research & Therapy          (2020) 12:117 Page 13 of 14
associate with the risk of future dementia and Alzheimer’s disease: the
National Finnish population study (FINRISK). Age (Dordr). 2016;38(5–6):
465–73.
28. Button EB, Robert J, Caffrey TM, Fan J, Zhao W, Wellington CL. HDL from an
Alzheimer’s disease perspective. Curr Opin Lipidol. 2019;30(3):224–34.
29. Zanoni P, Khetarpal SA, Larach DB, Hancock-Cerutti WF, Millar JS, Cuchel M,
DerOhannessian S, Kontush A, Surendran P, Saleheen D, et al. Rare variant in
scavenger receptor BI raises HDL cholesterol and increases risk of coronary
heart disease. Science (New York, NY). 2016;351(6278):1166–71.
30. Zhong VW, Van Horn L, Cornelis MC, Wilkins JT, Ning H, Carnethon MR,
Greenland P, Mentz RJ, Tucker KL, Zhao L, et al. Associations of dietary
cholesterol or egg consumption with incident cardiovascular disease and
mortality. Jama. 2019;321(11):1081–95.
31. Holzer M, Trieb M, Konya V, Wadsack C, Heinemann A, Marsche G. Aging
affects high-density lipoprotein composition and function. Biochim Biophys
Acta. 2013;1831(9):1442–8.
32. Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, Chamontin B,
Dartigues JF, Vellas B, Andrieu S. Antihypertensive drugs, prevention of
cognitive decline and dementia: a systematic review of observational
studies, randomized controlled trials and meta-analyses, with discussion of
potential mechanisms. CNS Drugs. 2015;29(2):113–30.
33. Nilsson SE, Read S, Berg S, Johansson B, Melander A, Lindblad U. Low
systolic blood pressure is associated with impaired cognitive function in the
oldest old: longitudinal observations in a population-based sample 80 years
and older. Aging Clin Exp Res. 2007;19(1):41–7.
34. Mossello E, Pieraccioli M, Nesti N, Bulgaresi M, Lorenzi C, Caleri V, Tonon E,
Cavallini MC, Baroncini C, Di Bari M, et al. Effects of low blood pressure in
cognitively impaired elderly patients treated with antihypertensive drugs.
JAMA Intern Med. 2015;175(4):578–85.
35. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A,
Walton I, Poulter R, Ma S, et al. Incident dementia and blood pressure
lowering in the Hypertension in the Very Elderly Trial cognitive function
assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet
Neurol. 2008;7(8):683–9.
36. Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, Murray
AM, Sullivan MD, Horowitz KR, Ding J, et al. Cognitive function and brain
structure in persons with type 2 diabetes mellitus after intensive lowering
of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern
Med. 2014;174(3):324–33.
37. Group SMIftSR, Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune
G, Cheung AK, Cleveland ML, Coker LH, Crowe MG et al: Effect of intensive
vs standard blood pressure control on probable dementia: a randomized
clinical trial. JAMA 2019, 321(6):553–561.
38. Qaseem A, Wilt TJ, Rich R, Humphrey LL, Frost J, Forciea MA, Clinical
Guidelines Committee of the American College of P, the Commission on
Health of the P, Science of the American Academy of Family P:
Pharmacologic treatment of hypertension in adults aged 60 years or older
to higher versus lower blood pressure targets: a clinical practice guideline
from the American College of Physicians and the American Academy of
Family Physicians. Ann Intern Med 2017, 166(6):430–437.
39. Gabin JM, Tambs K, Saltvedt I, Sund E, Holmen J. Association between
blood pressure and Alzheimer disease measured up to 27 years prior to
diagnosis: the HUNT Study. Alzheimers Res Ther. 2017;9(1):37.
40. Ostergaard SD, Mukherjee S, Sharp SJ, Proitsi P, Lotta LA, Day F, Perry JR,
Boehme KL, Walter S, Kauwe JS, et al. Associations between potentially
modifiable risk factors and Alzheimer disease: a Mendelian randomization
study. PLoS Med. 2015;12(6):e1001841 discussion e1001841.
41. Webb AJS. Progression of arterial stiffness is associated with midlife diastolic
blood pressure and transition to late-life hypertensive phenotypes. J Am
Heart Assoc. 2020;9(1):e014547.
42. Jiang Y, Shang S, Li P, Chen C, Dang L, Wang J, Huo K, Deng M, Wang J, Qu
Q. Pulse pressure is associated with plasma amyloid-beta transport
dysfunction. J Hypertens. 2018;36(3):569–79.
43. Oomura Y, Hori N, Shiraishi T, Fukunaga K, Takeda H, Tsuji M, Matsumiya T,
Ishibashi M, Aou S, Li XL, et al. Leptin facilitates learning and memory
performance and enhances hippocampal CA1 long-term potentiation and
CaMK II phosphorylation in rats. Peptides. 2006;27(11):2738–49.
44. Li TC, Yang CP, Tseng ST, Li CI, Liu CS, Lin WY, Hwang KL, Yang SY, Chiang
JH, Lin CC. Visit-to-visit variations in fasting plasma glucose and HbA1c
associated with an increased risk of Alzheimer disease: Taiwan diabetes
study. Diabetes Care. 2017;40(9):1210–7.
45. Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS,
Roat-Shumway S, Myoraku A, Reiss AL, et al. Neural correlates of liraglutide effects
in persons at risk for Alzheimer’s disease. Behav Brain Res. 2019;356:271–8.
46. Pike CJ. Sex and the development of Alzheimer’s disease. J Neurosci Res.
2017;95(1–2):671–80.
47. Neu SC, Pa J, Kukull W, Beekly D, Kuzma A, Gangadharan P, Wang LS, Romero
K, Arneric SP, Redolfi A, et al. Apolipoprotein E genotype and sex risk factors
for Alzheimer disease: a meta-analysis. JAMA Neurol. 2017;74(10):1178–89.
48. Riedel BC, Thompson PM, Brinton RD. Age, APOE and sex: triad of risk of
Alzheimer’s disease. J Steroid Biochem Mol Biol. 2016;160:134–47.
49. Della Torre S, Mitro N, Fontana R, Gomaraschi M, Favari E, Recordati C, Lolli F,
Quagliarini F, Meda C, Ohlsson C, et al. An essential role for liver ERalpha in
coupling hepatic metabolism to the reproductive cycle. Cell Rep. 2016;15(2):360–71.
50. Coley N, Ngandu T, Lehtisalo J, Soininen H, Vellas B, Richard E, Kivipelto M, Andrieu
S, Hatice F, groups MD: Adherence to multidomain interventions for dementia
prevention: data from the FINGER and MAPT trials. Alzheimers Dement. 2019;15(6):
729–41.
51. Kim YJ, Han JW, So YS, Seo JY, Kim KY, Kim KW. Prevalence and trends of
dementia in Korea: a systematic review and meta-analysis. J Korean Med Sci.
2014;29(7):903–12.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Lee et al. Alzheimer's Research & Therapy          (2020) 12:117 Page 14 of 14
